Table 3.
Univariable and multivariable OR for CVD risk and biomarkers in early and late samples combined
| Biomarkers | Unadjusted OR (95% CI) | P value | Adjusted* OR (95% CI) | P value |
|---|---|---|---|---|
| |
(a)Biomarkers as categorical variables |
|||
|
t-PA, ng/ml |
|
|
|
|
| <=8.7 (n=61) |
1.00 |
|
1.00 |
|
| 8.7-14.8 (n=60) |
3.87 (1.61, 9.31) |
0.003 |
1.58 (0.33, 7.65) |
0.571 |
| >14.8 (n=62) |
3.23 (1.35, 7.76) |
0.009 |
0.66 (0.12, 3.75) |
0.642 |
| Not measured (n=16) |
3.92 (1.42, 10.84) |
0.008 |
0.81 (0.09, 7.07) |
0.853 |
|
PAI-1, ng/ml |
|
|
|
|
| <=112 (n=63) |
1.00 |
|
1.00 |
|
| 112-207 (n=61) |
1.03 (0.45, 2.32) |
0.950 |
1.94 (0.37, 10.33) |
0.435 |
| >207 (n=65) |
1.87 (0.86, 4.04) |
0.113 |
2.15 (0.48, 9.63) |
0.318 |
| Not measured (n=12) |
1.70 (0.62, 4.64) |
0.300 |
0.52 (0.04, 7.73) |
0.637 |
|
D-dimer, ng/ml |
|
|
|
|
| <=67 (n=48) |
1.00 |
|
1.00 |
|
| 67-125 (n=48) |
0.71 (0.30, 1.72) |
0.451 |
0.49 (0.10, 2.27) |
0.360 |
| >125 (n=49) |
0.71 (0.30, 1.72) |
0.450 |
1.03 (0.18, 5.80) |
0.972 |
| Not measured (n=31) |
1.27 (0.58, 2.76) |
0.552 |
1.01 (0.21, 4.84) |
0.987 |
|
hsCRP, mg/L |
|
|
|
|
| < 0.9 (n=60) |
1.00 |
|
1.00 |
|
| 0.9-3.3 (n=62) |
1.90 (0.81, 4.46) |
0.142 |
5.70 (1.00, 32.51) |
0.050 |
| >3.3 (n=61) |
3.63 (1.59, 8.29) |
0.002 |
8.00 (1.23, 51.94) |
0.029 |
| Not measured (n=17) |
2.29 (0.84, 6.28) |
0.107 |
0.94 (0.06, 15.95) |
0.968 |
|
IL-6, pg/ml |
|
|
|
|
| < 0.3 (n=62) |
1.00 |
|
1.00 |
|
| 0.3-1.9 (n=62) |
1.89 (0.81, 4.41) |
0.143 |
2.69 (0.54, 13.40) |
0.227 |
| >1.9 (n=64) |
3.94 (1.74, 8.90) |
<.001 |
6.91 (1.21, 39.49) |
0.030 |
| Not measured (n=13) |
2.69 (0.94, 7.67) |
0.065 |
0.92 (0.06, 14.95) |
0.954 |
|
P-selectin, ng/ml |
|
|
|
|
| < 157 (n=62) |
1.00 |
|
1.00 |
|
| 157-236 (n=62) |
0.95 (0.42, 2.13) |
0.898 |
1.45 (0.29, 7.30) |
0.649 |
| >236 (n=64) |
1.95 (0.91, 4.17) |
0.085 |
6.20 (1.07, 35.89) |
0.042 |
| Not measured (n=13) |
1.57 (0.58, 4.26) |
0.378 |
0.66 (0.04, 10.09) |
0.766 |
| |
(b)Biomarkers as continuous variables (Log Scale) |
|||
|
t-PA, ng/ml |
|
|
|
|
| per log2 higher |
1.68 (1.09, 2.59) |
0.019 |
1.15 (0.52, 2.56) |
0.736 |
|
PAI-1, ng/ml |
|
|
|
|
| per log2 higher |
1.12 (0.84, 1.48) |
0.449 |
1.20 (0.71, 2.04) |
0.498 |
|
D-dimer, ng/ml |
|
|
|
|
| per log2 higher |
1.01 (0.79, 1.31) |
0.911 |
0.89 (0.57, 1.38) |
0.598 |
|
hsCRP, mg/l |
|
|
|
|
| per log2 higher |
1.37 (1.14, 1.66) |
<.001 |
1.54 (1.03, 2.30) |
0.036 |
|
IL-6, pg/ml |
|
|
|
|
| per log2 higher |
1.08 (0.90, 1.30) |
0.408 |
1.22 (0.85, 1.74) |
0.281 |
|
P-selectin, ng/ml |
|
|
|
|
| per log2 higher | 1.70 (1.05, 2.75) | 0.032 | 3.35 (1.20, 9.38) | 0.022 |
Conditional Logistic Regression Model; CI = confidence interval; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; IL-6 = interleukin-6; IQR = interquartile range; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; OR = odds ratio; PAI-1 = plasminogen activator inhibitor-1; PI = protease inhibitor; t-PA = tissue plasminogen activator.
*Adjusted for calendar year, duration of time between the date of samples and the analysis time, age, total cholesterol, HDL, CD4+ cell count and viral load, cumulative exposure to NRTI, NNRTI and PI prior to sample, and co-infection with hepatitis B or C.